PL1763343T3 - Trifluorooctan sodu do wytwarzania leków antyangiogennych - Google Patents

Trifluorooctan sodu do wytwarzania leków antyangiogennych

Info

Publication number
PL1763343T3
PL1763343T3 PL05758830T PL05758830T PL1763343T3 PL 1763343 T3 PL1763343 T3 PL 1763343T3 PL 05758830 T PL05758830 T PL 05758830T PL 05758830 T PL05758830 T PL 05758830T PL 1763343 T3 PL1763343 T3 PL 1763343T3
Authority
PL
Poland
Prior art keywords
antiangiogenetic
medicaments
preparing
calcium trifluoroacetate
trifluoroacetate
Prior art date
Application number
PL05758830T
Other languages
English (en)
Inventor
Rosa Gobbi
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of PL1763343T3 publication Critical patent/PL1763343T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
PL05758830T 2004-06-24 2005-06-17 Trifluorooctan sodu do wytwarzania leków antyangiogennych PL1763343T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT001279A ITMI20041279A1 (it) 2004-06-24 2004-06-24 Uso di calcio trifluoroacetato per la preparazione di medicamenti ad effetto anti-angiogenetico
PCT/EP2005/006533 WO2006000339A2 (en) 2004-06-24 2005-06-17 Calcium trifluoroacetate for preparing antiangiogenetic medicaments
EP05758830A EP1763343B1 (en) 2004-06-24 2005-06-17 Calcium trifluoroacetate for preparing antiangiogenetic medicaments

Publications (1)

Publication Number Publication Date
PL1763343T3 true PL1763343T3 (pl) 2010-07-30

Family

ID=35134535

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05758830T PL1763343T3 (pl) 2004-06-24 2005-06-17 Trifluorooctan sodu do wytwarzania leków antyangiogennych

Country Status (12)

Country Link
US (1) US20070260088A1 (pl)
EP (1) EP1763343B1 (pl)
JP (1) JP4903694B2 (pl)
AT (1) ATE453388T1 (pl)
DE (1) DE602005018642D1 (pl)
DK (1) DK1763343T3 (pl)
ES (1) ES2339263T3 (pl)
IT (1) ITMI20041279A1 (pl)
PL (1) PL1763343T3 (pl)
PT (1) PT1763343E (pl)
SI (1) SI1763343T1 (pl)
WO (1) WO2006000339A2 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007058360B3 (de) * 2007-12-03 2009-04-30 Heraeus Quarzglas Gmbh & Co. Kg Verfahren zur Herstellung einer erhabenen Markierung auf einem Glasgegenstand
EP2796135A1 (en) * 2013-04-22 2014-10-29 Polichem S.A. Use of trifluoroacetic acid and salts thereof to treat hypercholesterolemia
EP2845591A1 (en) 2013-09-04 2015-03-11 Polichem S.A. Use of trifluoroacetic acid as keratolytic agent to treat hyperkeratotic skin lesions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880660A (en) * 1987-08-28 1989-11-14 Minnesota Mining And Manufacturing Company Method for priming hard tissue
IT1236512B (it) * 1989-10-06 1993-03-11 Eniricerche Spa Elettrolita polimerico solido a base poliepossidica.
UA32427C2 (uk) * 1993-10-15 2000-12-15 Елі Ліллі Енд Компані Застосування бензотіофенів або їх фармацевтично прийнятних солей або сольватів для інгібування ангіогенезу і/або ангіогенних захворювань
US5593987A (en) * 1993-12-21 1997-01-14 Eli Lilly And Company Methods of inhibiting breast disorders
US6380366B1 (en) * 1994-04-28 2002-04-30 Les Laboratoires Aeterna Inc. Shark cartilage extract:process of making, methods of using and compositions thereof
US6083990A (en) * 1997-04-02 2000-07-04 Pharmos Corporation Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones
US6703050B1 (en) * 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
IT1317001B1 (it) * 2000-03-13 2003-05-26 Sigma Tau Ind Farmaceuti Uso della spirolaxina per il trattamento di patologie associate ad unaalterata angiogenesi.
AU2002236476A1 (en) * 2000-11-20 2002-05-27 Smith Kline Beecham Corporation Novel compounds
ITMI20011495A1 (it) * 2001-07-12 2003-01-12 Pharmaproducts Uk Ltd Sali di calcio ad attivita' citotossica
ITMI20040665A1 (it) * 2004-04-02 2004-07-02 Pharmaproducts Uk Ltd Sale di calcio per il trattamento della psoriasi e di dermatiti

Also Published As

Publication number Publication date
SI1763343T1 (sl) 2010-05-31
WO2006000339A2 (en) 2006-01-05
ATE453388T1 (de) 2010-01-15
US20070260088A1 (en) 2007-11-08
EP1763343B1 (en) 2009-12-30
DK1763343T3 (da) 2010-05-03
DE602005018642D1 (de) 2010-02-11
ITMI20041279A1 (it) 2004-09-24
PT1763343E (pt) 2010-03-24
EP1763343A2 (en) 2007-03-21
WO2006000339A3 (en) 2006-08-03
JP4903694B2 (ja) 2012-03-28
JP2008503517A (ja) 2008-02-07
ES2339263T3 (es) 2010-05-18

Similar Documents

Publication Publication Date Title
EP1335661A4 (en) PREPARATION OF MICRO BEADS
AU305723S (en) Bottle
TW200730211A (en) System and method of delivering radiation therapy to a moving region of interest
WO2007146959A3 (en) Pan-cell surface receptor- specific therapeutics
TW200642682A (en) A combination of medical drugs to augment the anti-cancer effect of chemotherapy
AU307881S (en) Bottle
AU309954S (en) Bottle
EP1888227A4 (en) ABSORBENT HYDROPHOBIC BORONATE GALACTOMANNAN COMPLEXES AND METHOD OF MANUFACTURING THEREOF
SG146451A1 (en) Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient
NZ597853A (en) Modified agrin-fragment capable of restoring muscle strength for use as a medicament
AU308100S (en) Bottle
MXPA04004306A (es) Uso de antagonistas del receptor de endotelina para el tratamiento de enfermedades tumorales.
PL1763343T3 (pl) Trifluorooctan sodu do wytwarzania leków antyangiogennych
AU309504S (en) Pen
EA200870177A1 (ru) Новый гликозилированный вариант fsh d3n
DE502006002907D1 (de) Verbandsmaterial mit wirkstoffen
GB2443377A (en) Anti-malarial composition comprising artesunate and lumefantrine
MY138088A (en) Use of deoxypeganine for treating clinical depression
MX2008011312A (es) Analogos de meridamicina para el tratamiento de trastornos neurodegenerativos.
TW200740825A (en) Cripowellins and synthetic derivatives thereof as medicaments
AU307302S (en) A chair
AU306632S (en) A chair
HK1113675A1 (en) Derivatives of 4-demethylpenclomedine, use thereof and preparation thereof
WO2004061408A3 (fr) Utilisation d’un inhibiteur non specifique du recepteur 5ht2b pour le traitement du cancer de la prostate
AU302015S (en) A bottle